{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:54:34Z","timestamp":1794322474080,"version":"4.9.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"4","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Venetoclax is a small molecule inhibitor of BCL-2 used in the treatment of acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL). Recent postmarketing studies of ibrutinib, another small molecule inhibitor, suggested that these agents may predispose to opportunistic infections. We sought to systematically review the randomized controlled trial (RCT) evidence of venetoclax to assess whether it predisposes patients to infectious adverse events (IAEs) and neutropenia. We systematically reviewed RCTs comparing venetoclax therapy with active or placebo controls for patients with hematologic malignancies. Data on IAEs and neutropenia were pooled by Bayesian meta-analysis, and we computed the probability of any increased risk (P[risk ratio (RR) &amp;gt; 1]) of IAEs or neutropenic complications. Seven RCTs were included, comprising 2067 patients. In CLL (n\u00a0= 1032), there was a low probability of increased risk of high-grade (P[RR &amp;gt; 1]\u00a0= 71.2%) and fatal IAEs (P[RR &amp;gt; 1]\u00a0= 64.5%) and high-grade neutropenia (P[RR &amp;gt; 1]\u00a0= 63.4%). There were insufficient data to perform a meta-analysis of IAEs in AML; however, 1 trial suggested an increased risk of IAEs with venetoclax. Furthermore, in AML (n\u00a0= 642), venetoclax was associated with a high probability of increased risk of high-grade neutropenia (P[RR &amp;gt; 1]\u00a0= 94.6%) and febrile neutropenia (P[RR &amp;gt; 1]\u00a0= 90.6%). Our results suggest that venetoclax has a low probability of increased risk of IAEs or neutropenia in CLL. By contrast, there is likely increased risk of high-grade neutropenia and febrile neutropenia in AML. Importantly, our analyses did not identify any specific IAEs that would benefit from routine antimicrobial prophylaxis or pre-emptive testing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011964","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T20:17:36Z","timestamp":1703794656000},"page":"857-866","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of\u00a0RCTs"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6790-220X","authenticated-orcid":false,"given":"Connor","family":"Prosty","sequence":"first","affiliation":[{"name":"1Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Katergi","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9773-3515","authenticated-orcid":false,"given":"Alex","family":"Nguyen","sequence":"additional","affiliation":[{"name":"1Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4222-6265","authenticated-orcid":false,"given":"Owen Dan","family":"Luo","sequence":"additional","affiliation":[{"name":"1Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sorin","sequence":"additional","affiliation":[{"name":"1Faculty of Medicine, McGill University, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Cherniak","sequence":"additional","affiliation":[{"name":"3Division of General Internal Medicine, Department of Medicine, McGill University Health Centre, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebag","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, McGill University, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Demir","sequence":"additional","affiliation":[{"name":"5Division of Infectious Diseases, Department of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0783-0624","authenticated-orcid":false,"given":"Emily G.","family":"McDonald","sequence":"additional","affiliation":[{"name":"3Division of General Internal Medicine, Department of Medicine, McGill University Health Centre, Montr\u00e9al, QC, Canada"},{"name":"6Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, QC, Canada"},{"name":"7Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-4239","authenticated-orcid":false,"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[{"name":"6Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, QC, Canada"},{"name":"7Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montr\u00e9al, QC, Canada"},{"name":"8Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Cheng","sequence":"additional","affiliation":[{"name":"6Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, QC, Canada"},{"name":"7Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montr\u00e9al, QC, Canada"},{"name":"8Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"issue":"7","key":"2024022615212565100_bib1","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41375-022-01596-z","article-title":"Changing causes of death in persons with haematological cancers 1975-2016","volume":"36","author":"Chen","year":"2022","journal-title":"Leukemia"},{"key":"2024022615212565100_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-319-04220-6_2","article-title":"Epidemiology of infections in cancer patients","volume":"161","author":"Zembower","year":"2014","journal-title":"Cancer Treat Res"},{"issue":"1","key":"2024022615212565100_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4065\/71.1.5","article-title":"Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy","volume":"71","author":"Yale","year":"1996","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"2024022615212565100_bib4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol"},{"issue":"21","key":"2024022615212565100_bib5","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.4254\/wjh.v7.i21.2344","article-title":"Hepatitis B virus reactivation with a rituximab-containing regimen","volume":"7","author":"Tsutsumi","year":"2015","journal-title":"World J Hepatol"},{"issue":"7","key":"2024022615212565100_bib6","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"26","key":"2024022615212565100_bib7","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024022615212565100_bib8","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024022615212565100_bib9","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"2024022615212565100_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clml.2019.10.004","article-title":"Risk of infection associated with ibrutinib in patients with B-cell malignancies: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Ball","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2024022615212565100_bib11","doi-asserted-by":"crossref","first-page":"100635","DOI":"10.1016\/j.blre.2019.100635","article-title":"Immunomodulatory effect of ibrutinib: reducing the barrier against fungal infections","volume":"40","author":"Maffei","year":"2020","journal-title":"Blood Rev"},{"issue":"7","key":"2024022615212565100_bib12","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/bloodadvances.2020001678","article-title":"Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors","volume":"4","author":"Ryan","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2024022615212565100_bib13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"2024022615212565100_bib14","volume-title":"FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukemia","year":"2020"},{"key":"2024022615212565100_bib15","volume-title":"FDA Approves Venetoclax for CLL and SLL","year":"2019"},{"issue":"4","key":"2024022615212565100_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024022615212565100_bib17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"2024022615212565100_bib18","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv"},{"key":"2024022615212565100_bib19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fphar.2019.00697","article-title":"Efficacy and safety of Bcl-2 inhibitor venetoclax in hematological malignancy: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Li","year":"2019","journal-title":"Front Pharmacol"},{"issue":"11","key":"2024022615212565100_bib20","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","author":"Bewersdorf","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"2024022615212565100_bib21","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2024022615212565100_bib23","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023)","year":"2023"},{"key":"2024022615212565100_bib24","unstructured":"Covidence\n          . Systematic review software, Veritas Health Innovation, Melbourne, Australia. Accessed 2 March 2023. https:\/\/www.covidence.org\/."},{"key":"2024022615212565100_bib25","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024022615212565100_bib26","volume-title":"Review Manager (RevMan). Version 5.4.1","year":"2020"},{"key":"2024022615212565100_bib27","article-title":"bayesmeta: Bayesian Random-Effects Meta-Analysis and Meta-Regression. Version 3.2","year":"2022","journal-title":"CRAN"},{"issue":"5","key":"2024022615212565100_bib28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1164\/rccm.202006-2381CP","article-title":"Using Bayesian methods to augment the interpretation of critical care trials. An overview of theory and example reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial","volume":"203","author":"Zampieri","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2024022615212565100_bib29","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/sim.6381","article-title":"Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis","volume":"34","author":"Turner","year":"2015","journal-title":"Stat Med"},{"key":"2024022615212565100_bib30","article-title":"meta: General Package for Meta-Analysis. Version 5.2-0","year":"2022","journal-title":"CRAN"},{"issue":"3","key":"2024022615212565100_bib31","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Softw"},{"issue":"12","key":"2024022615212565100_bib32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2024022615212565100_bib33","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024022615212565100_bib34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024022615212565100_bib35","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evidence"},{"issue":"24","key":"2024022615212565100_bib36","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"23","key":"2024022615212565100_bib37","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2024022615212565100_bib38","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024022615212565100_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2024022615212565100_bib40","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2024022615212565100_bib41","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJMc1600328","article-title":"Ibrutinib for chronic lymphocytic leukemia","volume":"374","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2024022615212565100_bib42","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2024022615212565100_bib43","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses"},{"issue":"8","key":"2024022615212565100_bib44","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024022615212565100_bib45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.18051","article-title":"Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent","volume":"197","author":"On","year":"2022","journal-title":"Br J Haematol"},{"issue":"23","key":"2024022615212565100_bib46","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv"},{"issue":"18","key":"2024022615212565100_bib47","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"24","author":"Davids","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/4\/857\/2215183\/blooda_adv-2023-011964-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/4\/857\/2215183\/blooda_adv-2023-011964-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T15:21:47Z","timestamp":1708960907000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/4\/857\/506893\/Risk-of-infectious-adverse-events-of-venetoclax"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011964","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]}}}